关于造血干细胞移植患者在植入前阶段粒细胞输血（GT）有效性和安全性的真实证据：一项来自印度北部的单中心研究，对印度关于GT的研究进行了小型回顾

IF 1.4 4区医学 Q4 HEMATOLOGY

Transfusion and Apheresis Science Pub Date : 2025-05-07 DOI:10.1016/j.transci.2025.104127

Pragya Silwal , Aseem Kumar Tiwari , Geet Aggarwal , Shubham Gupta , S.P. Yadav , Nitin Sood

{"title":"关于造血干细胞移植患者在植入前阶段粒细胞输血（GT）有效性和安全性的真实证据：一项来自印度北部的单中心研究，对印度关于GT的研究进行了小型回顾","authors":"Pragya Silwal , Aseem Kumar Tiwari , Geet Aggarwal , Shubham Gupta , S.P. Yadav , Nitin Sood","doi":"10.1016/j.transci.2025.104127","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Pre-engraftment phase of hematopoietic stem cell transplant (HSCT) (<3 weeks after transplant) is a crucial period with chances of early complications like febrile neutropenia. Granulocyte transfusion (GT) is a temporary bridge therapy to recover such patients till engraftment.</div></div><div><h3>Methods</h3><div>This was a retrospective observational study conducted by the department of Transfusion Medicine at a large tertiary care hospital in North India from January 2020 to June 2023. The study included all consecutive HSCT patients who received GT(s) during the pre-engraftment phase.</div></div><div><h3>Results</h3><div>Granulocyte was transfused to all post-HSCT patients fulfilling the criteria for GT. Donors were screened as per standard guidelines and apheresis was done for accepted donors. The mean dose of the product was 1.45 × 10<sup>10</sup> and the mean comparison of pre- and post-procedure neutrophil count was statistically significant (<0.05). There was successful 30-day survival in all the patients.</div></div><div><h3>Conclusion</h3><div>Although various studies have been done to prove the efficacy of GT, further research is recommended to formulate standard Indian guidelines.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 3","pages":"Article 104127"},"PeriodicalIF":1.4000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-world evidence on effectiveness and safety of granulocyte transfusion (GT) during pre-engraftment phase in hematopoietic stem cell transplant patients: A single-centre study from north India, with mini-review of Indian studies on GT\",\"authors\":\"Pragya Silwal , Aseem Kumar Tiwari , Geet Aggarwal , Shubham Gupta , S.P. Yadav , Nitin Sood\",\"doi\":\"10.1016/j.transci.2025.104127\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Pre-engraftment phase of hematopoietic stem cell transplant (HSCT) (<3 weeks after transplant) is a crucial period with chances of early complications like febrile neutropenia. Granulocyte transfusion (GT) is a temporary bridge therapy to recover such patients till engraftment.</div></div><div><h3>Methods</h3><div>This was a retrospective observational study conducted by the department of Transfusion Medicine at a large tertiary care hospital in North India from January 2020 to June 2023. The study included all consecutive HSCT patients who received GT(s) during the pre-engraftment phase.</div></div><div><h3>Results</h3><div>Granulocyte was transfused to all post-HSCT patients fulfilling the criteria for GT. Donors were screened as per standard guidelines and apheresis was done for accepted donors. The mean dose of the product was 1.45 × 10<sup>10</sup> and the mean comparison of pre- and post-procedure neutrophil count was statistically significant (<0.05). There was successful 30-day survival in all the patients.</div></div><div><h3>Conclusion</h3><div>Although various studies have been done to prove the efficacy of GT, further research is recommended to formulate standard Indian guidelines.</div></div>\",\"PeriodicalId\":49422,\"journal\":{\"name\":\"Transfusion and Apheresis Science\",\"volume\":\"64 3\",\"pages\":\"Article 104127\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Transfusion and Apheresis Science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1473050225000618\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion and Apheresis Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1473050225000618","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

造血干细胞移植（HSCT）的移植前阶段（移植后3周）是发生发热性中性粒细胞减少等早期并发症的关键时期。粒细胞输注（GT）是一种暂时的桥梁治疗，以恢复患者直到植入。方法本研究是由印度北部一家大型三级医院输血医学部于2020年1月至2023年6月进行的回顾性观察性研究。该研究包括所有在移植前阶段接受GT治疗的连续HSCT患者。结果所有符合GT标准的hsct后患者均输注了粒细胞。按照标准指南筛选供体，对接受供体进行了单采。产品的平均剂量为1.45 × 1010，术前和术后中性粒细胞计数的平均比较有统计学意义（<0.05）。所有患者均成功存活30天。结论：虽然已有多项研究证明了GT的有效性，但建议进一步研究以制定标准的印度指南。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Real-world evidence on effectiveness and safety of granulocyte transfusion (GT) during pre-engraftment phase in hematopoietic stem cell transplant patients: A single-centre study from north India, with mini-review of Indian studies on GT

Introduction

Pre-engraftment phase of hematopoietic stem cell transplant (HSCT) (<3 weeks after transplant) is a crucial period with chances of early complications like febrile neutropenia. Granulocyte transfusion (GT) is a temporary bridge therapy to recover such patients till engraftment.

Methods

This was a retrospective observational study conducted by the department of Transfusion Medicine at a large tertiary care hospital in North India from January 2020 to June 2023. The study included all consecutive HSCT patients who received GT(s) during the pre-engraftment phase.

Results

Granulocyte was transfused to all post-HSCT patients fulfilling the criteria for GT. Donors were screened as per standard guidelines and apheresis was done for accepted donors. The mean dose of the product was 1.45 × 10¹⁰ and the mean comparison of pre- and post-procedure neutrophil count was statistically significant (<0.05). There was successful 30-day survival in all the patients.

Conclusion

Although various studies have been done to prove the efficacy of GT, further research is recommended to formulate standard Indian guidelines.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Transfusion and Apheresis Science 医学-血液学

CiteScore

3.60

自引率

5.30%

发文量

181

审稿时长

42 days

期刊介绍： Transfusion and Apheresis Science brings comprehensive and up-to-date information to physicians and health care professionals involved in the rapidly changing fields of transfusion medicine, hemostasis and apheresis. The journal presents original articles relating to scientific and clinical studies in the areas of immunohematology, transfusion practice, bleeding and thrombotic disorders and both therapeutic and donor apheresis including hematopoietic stem cells. Topics covered include the collection and processing of blood, compatibility testing and guidelines for the use of blood products, as well as screening for and transmission of blood-borne diseases. All areas of apheresis - therapeutic and collection - are also addressed. We would like to specifically encourage allied health professionals in this area to submit manuscripts that relate to improved patient and donor care, technical aspects and educational issues. Transfusion and Apheresis Science features a "Theme" section which includes, in each issue, a group of papers designed to review a specific topic of current importance in transfusion and hemostasis for the discussion of topical issues specific to apheresis and focuses on the operators'' viewpoint. Another section is "What''s Happening" which provides informal reporting of activities in the field. In addition, brief case reports and Letters to the Editor, as well as reviews of meetings and events of general interest, and a listing of recent patents make the journal a complete source of information for practitioners of transfusion, hemostasis and apheresis science. Immediate dissemination of important information is ensured by the commitment of Transfusion and Apheresis Science to rapid publication of both symposia and submitted papers.